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DETERMINRT10N FDR FRT~「Y RCID PROPORT10NS
OF SERUM RND LYMPHOCVTE PHOSPHOLIPIDS
Yutaka Nasu (Nagano Co‖ege of Nursing)
1.Separation of BIood Samples to Mononuctear CeWs and Serum
Equipment and Reagents needed
Equients
1)falCOn tubes(sample number X 3)
2)pipettes Of 1 0 or 20mI(sample number X 3)
3)pasteur pipettes





1)Put biOOd samples into the falcon tube.
2)To 12n∩l of blood samples add the same amount of PBS(PhOSphate
Buffer Saline)and mix using the pipet.
(TO make the total amount of 25mlis preferable.)
3)Add carefully at the bottom of the sample 3mi of Limphoprep with
pasteur pipet.
4)Centrifuge at l,600r.p.m.for 40 minutes.
5)After separation suck up the lymphocytes at the middle phase very
carefuHy with pasteur pipet and put it to another falcon tube.
6)Suck up the serum phase(the upper phase)and stock in the freezer.
7)Add the lymphocytes so much of Buffer(PBS),m枚using the same
pipet,and spin at 800 rBp.rn.for 1 0 rninutes.
8)FIow away the Buffer and and add newiy,and spin again.
9)Repeat 8)at ieaSt One more time.





By making contact with organic soivent, lipid fraction of the serunn moves
tO solvent phase.
Equipment and Reagents needed
Equipment
1)giaSS tubes top covered with black cap[Sample No.X3]
2)l mi pipet[Sample NoE X 2],5 mi pipet[5]
3)thin pipet(Pasteur Pipettes)[sample NoB X 2}
4)beaker 50mi[5]
5)mess Cytinder 50mi[1],100mI[1]






4)The m枚ture of chioroform:methanol=1:1
5)nitrOgen gas
Preparation and Actions
1)Put l mi Of serum sample into the giass tube and add at first 2.5mi of
methanol and then l.25n∩I chioroforrn.This should be a clear one phase
system.
2)Add 1 0 μ 0f antioxygen with Hamitton syringe,・and after washing the
syringe, add 55 μl of standard phospholipid.
3)Wait and mix gently for 1 0 t0 1 5 minutes.
4)Add 3.75mi of chioroform and O.9mi of Water(if Sample volume is O.5mi,
then add l.4ml water),and Spin the tube at 3,000 rap.m.,for 1 0 rYlinutes.
AMPS shOuld not go over 9.
5)After the spin if the mixture separates clearty to two phases holding
protein between phases,suck up the chiOrophor『Ⅵ phase (the 10Wer
phase)with thin pipet and put it to another tube.
6)if the Separation is not ctear,for example the protein setties on the
bottonl,suck up the chioroforrn phase with thin pipet, put it to another
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tube and add l mi of chioroforrn and l ml of water, and again make the
spln.
7)After the separation and chioroforrn phase sucked up,rnake the
irjection with nitrogen gas for the evaporation of chioroforrn and
continue tili chiorofor『Ⅵ completely goes away.
(ThiS iS tO be made within almost 1 5 minutes.But be carefui not to touch
the tip for gas to the liquidB)
8)As soon as the ittectiOn is over,add O.05mI(50μりOf Chioroform and
methanol(1:1)m嵌ture and bttng the test tube to the freezer.
3.Fractionization of Lipid with Thin Layer Chromatography















4)the m改ture of chioroform―methanol―water―acetic acid
chioroforrm   100
methano1     100
disti‖ed water 20





1)Activate the thin tayer at l1 0 qC for 2 hrs.
2)Prepare the soivent rnixture in the chamber and make a few
rninutes evaporation.
3)Prepare chioroform for washing Hamilton syringe.
4)Bring the standard and the sample frorvl the freezer.
5)Draw the lines for spotting with a pencil on the thin tayer.
6)Spotting
(1)WaSh Hamilton syringe with chiOroform several times.
(2)Make Spots along the left lane with 5 μl of standard.
(3)Wash Syttnge with chioroform several times.
(4)Make Spots along the centre lane with 5 μI(for example)of Sample.
(5)Make Spots along the right iane with 50 μI(fOr example)Of Sample.
Do not touch the syringe to ssilica and make spot siowiy as the
solvent never spread too widety.
7)Put the thin tayer into the chamber and keep it straight up,and do not
make only one side touch solvent earlier than another side.And be
carefui the lanes should be a littie higher than soiVent level.
(llVith this fractionization,(1)neutral lipids,(2)free fatty acids,(3)free
cholesterol, and(4)phosphOlipids separate.
We want to get the 4th one.It would be co10red with yeliow.)
8)After the solvent are absorbed into thin layer to its tOp,put it out and
dry.
9)After drying, stain only standard iane with iodine.
Staining would damage phospholipid. So to Stain with iodine onty
standard lane keep other ianes covered with something.
The staining should be rnade by bloWing nitrogen gas through giass tube
holding iodine inside among cotton phases.
10)Draw the square surrounding each sample tane with a pencil and cut the
sillica along the pencil line with needle to isolate each band.
11)BIOW Water to each Square using thin pipet.
12)Cut the wet part of cillica with thin spatula and put the cutted cillica
into the glass tube.
13)Add l mi of Chioroform―methanol―water―acetic acid mixture and shake
a couple of rninutes.
14)Spin and down the sillica with 3,000r.p.m.for 5 minutes.
15)Extract silica one more time with same solvent.
16)Take up the solvent and make evaporation with nitrogen gas.
















1)Evaporate the sample into dryness.
2)Add l mi of Methanol containing l%suifu面c acid.
3)Keep the sample in black capped tubes overnight at 50℃.
4)Let the tubes cool,and add lrni H20+2mI Hexane,
vortex,or turn around about 50 times.
5)Centrifuge at 2,000 rpm for 5 minutes.
6)Suck the 10wer phase with pasteur and discard it.
(lf the silica pieces are fioating,then suck the upper phase and put it to
another tube.AIways better to take this way.)
7)Evaporate the upper phase(whiCh iS teft)and add l mi of absolute
ethanol.
8)Evaporate this and add 20-30 μl of Hexane.
5.The MethyI Esters of Fatty Acids Analysis in a HP 5890 Gas
Chromatograph Using OV 351 Sillica Capillary Column












l)CiOSe the oven door.
2)(Dpen the gas cock Of Hydrogen gas and Air gas cytinder,but never touch
Nitrogen Gas cytinder.
[1]main cock
[2]sub cOCk:Attust HydrOgen to 2.9,and Air to 2,as indicated on the
meter with magic ink.
3)Open the gas tube over lhe Oven.(Take off the cock.)
4)Put the WcooIW SWitch Of MODE off.
5)Put the main sWitches of MODE,PROGRAMMER and ELECTROMETER on,
and also recorder on.Then recorder indicates I'readyI'.
6)Put injector lever to the arrowed place(=275),and When the itteCtOr
iamp begins I'on and offW successively,everything is ready for beginning
gas chromatograph.
7)Attust the Hydrogen gas pressure of FRACTOVAP to l and Air to O.8.
8)Put the ignissiOn sWitch Of ELECTROMETER down,keeping it down TILL
THE TOP HAT OF CENSOR JUMPS UP,and then automatically it wili be
recovered.(SOmetimes it bombs).
9)InCrease Air pressure to l.
Decrease Hydrogen pressure sioWly to O.5.
10)PrOgrarnrYle iS already set and never touch them日


















I‖B Operating the Machine
l)BefOre injection wash syringe with chroloform or absolute EtOH 1 0
tirnes.
2)Make ittectiOn Of the sample.(5uljust enougha)
injection must be made carefully and rapidly.A‖sample liquid n the
syttnge must be injected at a time.
3)Make Start of the[1]PROGRAMMER,[2]INTEGRATOR just after the
injection日
4)Wttte away on the margin of the chart a‖your knowiedges about
working sample.
IV.Ending of Gas Chromatograph Work
l)ELECTROMETER main switch off.
2)PROGRAMMER main switch off.
3)WcooIW SWitch of MODE ON.
4)Open the even door.
5)INJECTOR off.
6)HydrOgen pressure to O.
Air pressure to O.
7)Ciose the main coCks and sub cocks of each gas cylinder,but never touch
the nitrogen gas cylinder.
8)integratOr off.
9)Wait at least 1 5 minutes.
10)CIOSe the gas tube.































POluunsaturated fattu aCidS in
plasma and mananuclear ce‖
phasphalipids of patients
L'ith atapic eczema
Yutaka Nasu(Nagano College of Nursing,Japan)
Kari K.Ektund(University of Heisinki,Finiand)
Ytto T.Konttinen(UniVersity of Heisinki,Fintand)
INWaDUCT10N
It has been known frorn 1 930s that dietary supplementation with essential
fatty acids should be of therapeutic value in atopic eczema. And in these
days it has been found that oral adr▼linistration of evening primrose oil(EPO)
makes atopic eczema improve.
Recent studies of polyunsaturated fatty acids(PUFA)in plaSma and blood
ceH components of patients with atopic diseases have indicated disordered
fat rnetabolisrvl as tinoleic acid(18:2n-6)tendS tO be increased while the
more unsaturated fatty acids, such as garnrna―linolenic cid(18:3n-6)and
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arachidonic acid(20:4n-6)are present in decreased amounts(Fig l ).In
atopic eczema patients, the delta-6-desaturase function should be irnpaired,
then the amount of linoleic acid should be increased,on the other hand those
of the linoleic acid metabolites should be decreased. And so when the direct
metabolite of linoleic acid, garnrYla―linolenic acid, is adrninistered for the
patients,then the symptoms of this disease should be disappeared.
It has also found that such an abnorrnality may not be restricted to
patients with atopic derrnatitis but can also be found in cases of
respiratory aHergy and other diseases.
On the other hand, Berth―」o es et al. indicates that essential fatty acid
supplrnentation has no effect for the improvement of atopic derrnatitis
according to their placebo―contro ed trialH
We had a chance to have severalinfant patients with atopic eczema and to
make them the treatment with Efamol.At the same time of this treatment,
we tried to measure the fatty acid Components in the serurn and the
mononuctear ceWs phospholipid, and also tried to get some blood data
concerning about the inflarYl『Ⅵation, and tried to make ctear the effect of




1 0 patients with atopic eczema aged from 4,7 to 13,7(mean age 8,03)
were entered into a trial of evening prirnrose oil in the treatment of atopic
eczema
The evening primrose oil used was Efamol,the seed oil from speciaHy bred
strain of Oenothera biennis which yields oil of a constant consumption.
BIood samples were drawn into EDTA―tre ted tubesフseparated within
hours of coHection and stored at-20℃ u til analysis.
To investigate phospholipid fatty acids in mononuctear celis(MNC),20mi
blood was drawn into an equal amount of Hank▼s balanced salt solution.MNC
were isolated by gradient centrifugion in FicoH―Hypaque(Pharr ac a).
8 children were norvlinated as control group(aged frOm 6,5 to 12,4),and
they were a‖ free of acute or chronic i‖ness, denied taking either rnedicinal
or drugs and had no personal or farnily history of atopy.
nSSauS
AII blood samples were taken after an overnight fast.The specirnens for
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trace elements and vitarnin analyses were coHected sirィluitaneousty with
the laboratory tests needed for control of drug therapy and to monitor the
disease activity.
The blood samples for trace elem9nt deterrYlination were drawn using
staintess steei needles(Venttect,Terumo,Beigium).Serum samples were
stored in polyethene tubes and kept at-20℃until analyzedtt Zinc and copper
concentrations were deterrⅥined by flame atorvlic absorption
spectrophotometry(AAS)(Perkin EImer 300 AAS)using a method deveioped
by Salrnela et al(1984). Selenium concentrations were deterrnined with a
fiameless AAS(Perkin EImer 5000,HGA 400)emp10ying the method
described by AIfthan and Kumpulainen(1985).A‖the trace lement
measurements were made in the same laboratory.
Fatty acid COmpositions of MNC and serum phospholipids were deterrnined
using a method developed by Willian∩W.Christie:
One ml of pure serum was extracted with 3,75n∩l of chioroforrγ1/methanol
(1/2),washed with 3,75 mi of chioroform and O,9mi Of Water,centrifuged
for 1 0 minutes and the lower phase(the chioroforrn phase)waS Separated
and evaporated by nitrogen gas.
After the evaporation O,05mi of methano1/chiorofornn(1/1)WaS added,and
fractioned with thin tayer chromatography(Kieseige1 60,Merck,Germany)
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into neutral lipids, free fatty acids, free cholesterol and phospholipids by
using hexane/diethyt ether/acetic acid(50/50/1)aS a sOivent. Phospholipid
fraction was scraped into black capped tubes and transmethytated in 10/o
H2S04 in dry methanol at 50℃ overnight.The resuiting methyl esters of
fatty acids were separated and measured using a Hewiett Packard 5880 gas
chromatography with a 6-foot column packed with 1 00/o silar on chromosorb
WAW 106/230.
The carrier gas was hydrogen(0,5kg/c請). Initial temperature of the oven
being 1 70て,,final temperature 240℃. Retention tirnes and peak areas were
automatica‖y computed by a HP 3390A integrator. Peaks were identified by
comparison with standard fatty acid methyt esters from Nuchek Prep. Inc.
(Elysian,Minnesota,U.S.A.),Figure 2 shows an example of gas
chromatographic chart from certain patient's serum identified each fatty
acid.
Evaluation of the resuits
The hardware used in this study was a....cOmputer at University of
Helsinki. Data were listed into DATABASE   version.AH statistical analysis
were performed using Biomedical dataprocessing program tibrary(BMDP,
version 1 994).
-26-
in before/after comparisons, the statistical significance was tested using




Table l shows the mean values of each fatty acid proportion per total fatty
acids in MNC, including samples frorn control groups, from patients before
treatment and from patients after treatmenta We could be available 4
control samples, 8 patients before treatment and 5 patients after
treatment.
No significant differences were seen between control and patients before
treatment.By the treatment of EFA,dihomogammaぃlin lenic ac d(20:4n-6)
was significantly decreased and behenic acid(22:ln-9?)signifiCantly
increased.
Linoleic acid(18:2n-6)of patients looked like to be increased compared
with control group and decreased after treatment,though not significantly.
And more unsaturated fatty acids, such as homogarnrna―linoleni  acid and
-27-
arachidonic acid iooked decreased after treatment. Lindskov and Hoetrner
has reported that in eczema patient MNC,the ratio of 20:4n-6/20:3n-6 in
total lipids(b)had been reduced.In this study,however,there could not
find any significant differences of this ratio between control group and
patient group before treatrnent.(Table l)
Table l also shows the mean values of each fatty acid proportion per total
fatty acids in serum on the same groups as above.The significant
differences were observed on 20:3n-6 between control and patients before,
and also between patients before and patients after. Another significant
difference was found on 20:4n-6 between patients before and patients after
The ratio of(18:3n-6+20:3n-6)/18:2n-6(a)in patient before was
significantly reduced compared with control, and iooked reduced again after
the treatment.
With matched t―test about serum value between patients before treatment
and those after treatment,significant differences were found on 1 8:1,
20:3n-6,20:4n-6,(18:3n-6+20:3n-6)/18:2n-6 and 20:4n-6/18:2n-6.  Fig4
shows the change of 20:3n-6 percentage to total fatty acids on each patient,
Fig5 about 20:4n-6,Fig6 about(18:3n-6+20:3n-6)/18:2n-6,Fig7 about
20:4n-6/18:2n-6.AIso in Fig8 about 1 8:2n-6. In many cases it has been said
that linoleic acid(18:2n-6)concentration increases in the serum of atopic
-28-
eczema patients,but in our study no significant tendency was ObServed on
18:2n-6.
DISCuSsloN
Atopic eczema is said tO be the condition in which an inherited sioW rate
of 6-desaturation has been best documented.Norrnal or elevated
concentrations of LA and ALA are associated with reduced concentrations of
their metabolites in umbilical cOrd bloOd, in the plasma and red ceHs of
children and aduits, in rnilk and in adipose tissue.
From our results we could not find any difference abOut linoleic acid in the
serum between control and patients with atopic eczema.
Schalin―Karrila et al. reported in 1 987 that the baseline fatty acid
composition of plasma phoSpholipids frorn the patients with atopic eczema
(yOung aduits)did nOt differ significantly frorYl that in the heaithy suゅ
jects,
except for a stightly iower ievel of oleic acid (18:ln-9).
on the other hand,Manku ct al.(1984)had reported that the mttor dietary
n-6 EFA, linoleic acid, Was Significantly elevated but aH its metabolites
were significantly reduced in the aduit patientslplasma. Beforehand Manku
-29-
et al. had made ciear about the fatty acid composition in plasma in norrnal
humans.
Strannegard et al.(1987):The fatty acid composition of serum lecithin
from children with atopic derrnatitis was found to be abnorrnal,
characterized by significantly increased proportion of linoleic acid and
reduced levels of metabolites of this fatty acid.
Lindskov et al.(1992):Exarnined the PUFA content in phospholipids derived
from plasma,red blood celis and mononuclear celis(MNC)in patients with
atopic dermatitis.(adultS).in plasma no significant differences were found
between patients and controls. The most significant findings in eczema
patient MNC were reduced ratios of 20:4n-6/20:3n-6 in total lipids and in




































Outline of the metabolism of essential fatty acids of n-6 series.























































An example of gas chromatography chart of rnethyl esters separated   from
a certain patientls serum.
According to the retention tirne peaks were identified by comparison with























































Fatty acid composition in MNC and in serur▼l of each group日
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AIphaBlinolenic acid in the treatment of rheumatoid arthritis□
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Abstract ln fheumatoid arthritis various pro―in tamrna‐
tory mctabolites or arachidOnic acid(AA), such as
ieukotriene B4(ETB4)and prOStaglandin E2(PGE2),
contributc to tissuc destruction and pain.In contrast to
AA,、vhich is an omcga-6 ratty acid, the omcga-3 ratty
acids,anef having been liberated rrom the ceH Incmbrane
phosphoLpids、 are rurthcr converted into the non‐ or
anti―naammatory eicosanoids LTB5 and PG13・ AA
conccntration is an ilnportant regulatory step in the
synthesis or both prostanoids and teukotriens. E》ietary
supplementation with eicosapentaenoic acid (EPA)
and docosahexaenoic acid(DHA)has thCrefore been
used to dccrcase the ratio of AA to EPA o「DHA to
obtain bcnchcial dinical effcctso EPA and DHA are
round in anilmal rat and are quite expensive compared
紀u肌 檻 恩 ご:i.龍l誌」£躍 常 群 溜 鶏 土濫 !
contro‖cd triat with alpha‐LNA in 22 paticnts with
fheumatoid arthfitis, using a hnoleic acid preparation
as a placebo. ARer a 3‐1■onth fonOw_up, thc treat‐
mcnt gfoup showed an increased bleeding til■e, but
thc dinical,sutteCttVc(BIobal assessment,classiaca苗on
of runctional status,joint score index, visual analoguc
scale,pain tcndereness score)and labOratory parameters
(haCl■Ogiobin,erythrocyte sedinientation rate,C‐reac‐
tive protein)did nOt Show any statistical alterations
AA,EPA and DHA did not change eitherin spite of a
significantincrcase in alpha‐LNA in the treatmcnt group.
D C E Nordstr6m C Fhman Y I Konttincn
Fourth Depariment or lヽedicine, Division or Rheumatology,
Hcisinki Univcrsity Central Hospital,Finiand
DCE.Nordstr5m V E A Honkanen Y Nasu,E.Antila
Y■Konttinen
Musc」ioskeletal Diseases and lnna■lmation Research Croup,In‐
stitute or Biomedicine,Department or Anatomy,University or
Hclsinki,Finiand
DCE.Nordstrёm(西0  .
Hclsinki University Central Hospital,Di宙sion or RheumatoloBy,
Unioninkatu 38.FIN‐00170,Hclsinki,Finiand
Thus,3‐month's supplementation with alpha‐LNA did
not prove to be bcncrici l in fheumatoid arthritis.




Rheumatoid arthfitis(RA)is an innammatory discase
involving multiple syno宙al joints.RA is associated with
he ciassical signs orinaammation,including vasodilata―
tion, edema,pain in movemcnt and joint tendemess.
These sym toms are probably to some cxtcnt duc to the
iocal production of pro‐naa.llnatory cicosanoids, in
particular prostaglandins(PG)such aS PGE2〔1l and
leukotienes(LT)such as LTB4〔2}Accordingty,non‐
steroidal anti‐inaammatory drugs(NSAIDs)are Widely
uscd in the treatlnent of RA.Onc important rnechanism
of action ofthese NSAID―type drugs is believcd to be a
dir ct enzymatic nhibition or thc Pc,I■2 Synthetasc en‐
zyme, which c talyses two subsequent reactions:「lr t,
5‐cyclo‐xygcnazation or arachidOnic acid(AA)into a
labilc nterinediate P(〕E2imm diatety foHowed by con―
vcrdon into PGH2;PGH2 iS further mctabolized into
pro‐inaanll.atory prostanoids such as PGE2・Steroids,
administercd intra‐art cul rly or systenlicaHy, arc even
morc c「lcicnt anti‐i nanll.atory d「ugs.This scems to be
duc to induction or lipomoduhn, which binds to ccH
membrane phospholipids and prevents the action of thc
enzymc phosphohpase A2, WhiCh otherwise would bc
ablc to cleave AA rrom cen mcmbrane phospholipids.
E)i∬inished production of AA dccrcases not only the
production of the above‐me oncd prostanoids, but
also the production or atternative AA products,namcty
various icukotricnes such as LTB4・ TheSc re usually
folHled from AA by the enzyme 5-lipoxygenase,which
converts AA into 8R, 15S―di―hydrOxyeicosatetraenoic
cid,which is rurthef rnetaboHzed into pro‐ina nll.atory
leukotricnes such as LTB4〔11・
-35-
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Becausc AA conccntration is an impOrtant rcgulatory
stcp in the synthesis ofboth prostanoids and lcukotricnes
t3〕,dictary supplementation with eicOsapentaenOic acid
(EPA)and dOCOSahexacnoic acid(DHA)has bCen used
to decrcase thc ratio O「AAto EPA and DHA.In contrast
to AA,EPA and DHA,arter ha宙ng bcen liberated from
the ce‖membrane phospholipids,are rurther converted
辮 誌 ェメ 監 :li:溜F粗駅
a解
配審 沼 塩 と,|!;:
weII documented i4-91.BCCausc EPA and DHA are




supplemcntatiOn by naxseed oil cOuld be a rational
alternativc.It has been speculated that alpha‐LNA could
bc benerlcial by twO ditFerent rneans:「lrs ,by being e10n‐
gated into 10ng{hain EPA‐and DHA‐type ratty acids
(and thus decreasing the AA “load")and SecOnd, by
compcting with hnoleic acid(LA)fof the Δ6…deSaturase
enzynle,which would lcad to fo二二 lation ofAA from LA,
and thus, dil■inェsh AA and inaamlnation caused by
metabolites thcfoi FurtheJHlore,alpha‐LNA could have
a steroid―l ke crect by decreasing production of bOth
早留第路 研甲 程 i“:Sttnュ平孟甲 at鰍 善F元評:
donlized study comparing alpha―LNA to“placebo"








Pafi獣〒 ≒辞 電 出
W&鍬
I!irk絡茸 《塁I程r岨吊 鳥 :Manitow∝,WiscOnsin,USA〉Patients werc randomized into two
groups. The treatinent Broup ingestcd 30 g or naxsced oil(320/。
alpha‐LNA)per day rOr 3 months,while the control group reccived
30 g or samowcr。‖(33%linoleic acid).The samOwcr oil and
靴笛乱撃選H総綜潔竃1:調¶起路研詔協檻
turer A larger dOsage has been shOwn io produ∝diarfhoea,and
some patients expc●enced ioose stools in thc present study.
Chnical assessment(pahent's and invesSgator's nvc_scale giob‐
al assessment,classinca6。no「runctional class[121,Kaarela's joint
score index(measuヽag joint iavolvement by swelむng or hmむtaSon
or motion in proximalinterphalangeal,metacarpophalangeali、v●st,
elbow, shOulderi t∝, metatarsophalangeal, subtaloidi talocrural,
kncc and hip joints on each ddc and∝Ⅳical spinci c ch joint
scottng one and the ma対mum joint score being 23)〔131,subiecttVe
ぞ灘鴛撃鴻e潔;呂ぜ‖賞路∵演i雷驚程器記∬t結
rate,C‐reaci市e prOtcin(CRP),haCmOglobin〕Were pcfrorrned by
the chie  investigator(DN)at the beginning and end Or the treat‐






verba‖y The pain threshOld leveis at dirrerent sites were nOrmahzed
訛謎l龍北品ぎ報t解電:琺沼r乱!獄と!乱習Yl遠
patient cOmphan∝
The ratty acid Prome(percentaBc
alPha‐LNA and LA;TaЫc 2)orscrurn




acids were analysed in a HP 5890
kard COmpany,Avondale,UsA)
colШmn(Nordion OゝHelSinki,
ed with a name ionization det∝‐
tor and HP3393A integrator
Table l Chnical data and outcome rcsults in aIPha‐linolcnic acid
















































































Table 2 Change in fatiy acid pronle in aIPha‐hnolenic acid trcat‐
ment and linoleic acid Piacebo groups
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hpid r tty acid prorilci artcr the codcs were opened,il was
hown that patients on alpha‐LNA spcci「lc Hy h d sig‐
nittcantly increased alpha―LNA serutt Vatucs(with nO
changcsin LA lcvcis)and,ViCC vcrsai patients on LA had
signi「lcantly increased LA vatues only.
Not only did the dietary intervendon have an OtteC‐
tive er∝t on the serum phosphohpid aatty acid prorlle
(TaЫe 2),but alSO thc bにeding imc was arectedi bcing
icngthened in patients on alpha‐LNA.This has also been
feported by others t17,18〕and haS been considcrcd to be
duc to the rapid turnover ofthe ccH Incmbrane phospho‐
hpids in the nuclear platclets and thus a rapid changc in
tipid mediators, including the pro―aggrcgatofy thronl‐
boxanc A2,rCleased upon platctct activation induccd by
surface contact[18〕.ThiS WdCOmed eFfcct of alpha―LNA
has also bcen uscd successfuny in the sccOndary preven‐
tion or coronary heart disease t18〕.
Contrary to expcctations, there was no chnical iHl‐
provcmcntin RA patients on alpha‐LNA(orLA;Table l).
In particular,it was ofinterest that there was no change
in the pain threshold in alpha‐LNA‐supplemented pa‐
tients.Itis known that PGE2,PC'12 and 8R,15S‐diHETE
(an inte111lediate in he LTB4 metabolism)scnddZe the
pril■ary afrerent nOciceptive ribrcs to subsequent stilnuh
including nechanical pressure[19,201.Ifthere had been
a ravourable erfect on the prostagiandin lnetabonsnl,this
could have led to a higher pain thrcshold in the soft
tissues also.However,this was not the case.
Incrcased intake oF(omega‐3)polyuns turatcd fatty
acids(PUFA)withOut adequate antioxidant protection
could rcsult in increased free radical folB41atiOn and lipid
peroxidation.Thus,when(omega_3)PUFAs are used to
reduce the inaanll.atory cvents of RA, their possible
adversc erFccts should be considered and preventcd〔21}
It has bcen shown that in paticnts with inttanllnatory
joint discase the synovial auid con∝ntration ofalpha―to‐
copherol is signiricantly IOwer rclativc to that or paired
serum samples t221.ThiS indicates the consumption of
alpha‐tocophcfol within the inaamed joint,perhaps due
to its folc in the telllttination of Lpid pero適dati .PUFAs
are casily oxidized and,therefore,thc antioxidant prot∝‐
tion shouid be propefty acknowiedged. NolHlaHy the
vegetable oils providc lipid‐s luble antioxidants in addi‐
tion to Fatty acids.
Alpha‐LNA and LA arethe mostabundamt PUFAsin
Westem diets, with LA body levels usuany exceeding
those or alpha_LNA.Itis thererore possible that a short‐
ten■supplementation for 3 1nonths only was not enough
to signiflcandy increase the alpha‐LNA:LA r tio.If that
werc the case,supplementation with alpha‐LNA would
not changc thc EPA and DHA prorlle.This was sup‐
portcd by the prescnt obscⅣations,because alpha‐LNA
supplcmentation increased the seruHl atpha‐LNA l veis
(P=0.04)but had nO erect whatsocvcr on EPA,DHA,
AA or other fatty acids(Table 2).Although minor cr∝ts
on'prostagiandin levcls Hught be possible t231,thiS Was
not renected in the chnical statusi clinical and labofatory
disease activity parameters were unaltered in patients re―









(b ror rarler treatment)
(%,SD)  (P valuc)(%,SD)  (P valuc)
Alpha‐linolenic acid     24」L029
しinoleic acid         l 13±389
Arachidonic acid   -004±073
Eicosapentaenoic acid  0 02」L038












The hardware used in the study was an IBM PC/A■Ali the
statistical aI,alyses were perronれed uSing Biomedical's data process‐
ing program(BMDP,version 1993).In berOrerarter compansons,
the statistical signincance tests werc pcrFomcd using paired r‐test
(BMDP3D)or variances Standard deぢadon(SD)was uSCd tO
indicate dispersion of results and a P valuc or ≦o.o5or iess w s
considered Statistica‖y s gni「icant.
Resul色
After 3.2±0 8 months orsupplCmentation,he serum aト
pha‐LNA acid con∝ntration(0.24±0.29,P=0.04)and
the biceding timc(1.03±3.13,P= ,35)were incrcased in
the naxseed oil group, and the LA c nccntra ion
(2.4±2.42,P=0.008)was inCreased in the samow r oil
group(TablCS l, 2),confl川】ling overaH patient compli‐
anceo None orthe chnical param tcrs northe co dition of
the paticnts improvcd in the aaxseed oil group(Tabic l).
Some or the parameters rcnccting discase activity iln‐
proved in the samower oil group(di∬ence in befor /a「
tcr values;aaxseed vs.safΠow r,haemogiobin,CRP).
The pain tenderncss score aSSessed by the doloirneter did
nOt changc in either Broup.
The traoe element sttitus renecting nutidonal potential
for desaturation(zinc)and fOr antio電dation(Seleniuin,
ZinC)Was as foIIows.¬he serum zinc was 12.2±1.6 μmolβ:
伍ve padents had iow serum zinc l vds(<1l μmOl'1)[11]・
The serum selenium was l16.2±21,2 μgμ.COppcr con―
∝ntrations rnay indicate inaaHllnatory act vityi the rnean
value of 23,7±4.2 μmolィI Was somewhat higher han he
uppcr hmit of no▲ニュal valucd of 22 μm 1/1〔11,Elcvcn
patients exceeded this uppcr lirnit valuc.
DIscusslon
Inaaπunation in RA is in part cause mctabohte f
AA and,thererOre,it ttight be ex ∝ted tha a d creased
ioad of AA could be benericial.To this end RA patients
were supplemented wiht eithcr alphaぃLNA or LA in a
double‐blind and randomized manner.Par ic pat on in
the study was voluntaりand patient complianc  se med
excenent.This was supportcd by the change,duing the




et al.[23〕have ShOWn that PG synthesis,but not ihe
'ヽ
まモi「;1阜;樟;;FrⅢ t°
AA is suppressed by alpha‐LNA
Some studies have indicated possible clinical bencrits
or supplementation by both ganllna‐linolenic acid Of the
omega‐6 series and by rish oils ofthc Omega‐3 seriesin the
activity.
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REDOX BALANCE IN RHEUMATOID ARTHRITIS: TRACE ELEMENTS AND VITAMINS
VERSUS DIET,DISEASE ACTIVITY AND MEDICATION
帝郎 途 躍 蹴 懃 :乳吼 ほ星:く器 IP'・
m。箭ぉ牡 Httkko S盟■1詢pO駒正前 武が,TuOm器
連韓H導軽榊t選静軽IIt耐鳴雨り
:鷲:舘電酷よ思i∵絣!温:漁「出:播評試配翠ty私鷺【紹駕:温鰍よほ::きalid Foundadon,H雨耐81nStitute of Molecular lπwnunology,lMospitai for Joint lDiseases,NY〔J MedicaI School
Key wordsi zinc,copper, selentum, superoxide dismutase, glutathione peroxidase, retinol, atpha―
tocopherol,retinol binding protein,nutrition,disease lnodirying anti_Theumatic drugs,sulphasalazin,
『heumatold arthritis
Cofrespondence to: Y「jO T.Konttinen,MD,PhD,Fourth Department of Medicine,Hclsinki
University Central】■ospital,Unioninkatu 38,SF-00200】阻etsinki,Finiand
INTRODUCTION
The interactions between the interphase or chronic inflarllnation,FnediCation and diet are not known.
We tackled this problern by combining new tools,Setti―N nutritional database developed at National
Hcalth lnstitute in Fintand and rnuitifactorial statistical analysis,with careful clinical and biochemical
characterization.RA provides a good lnodel for such purposes and was subjected to a detaited study.
Abbreviations usedi RA = fheumatoid arthritisi RF = rheumatoid factori CSHpx = Blut4thione
peroxidasei SOD = superoxide dismutasei RBP = retinol bindinB proteini IL―I = interi ukin-1;
DMARD=disease modyfying anti―『heumatic druBI RDA=recommended daily aliowancei ROS=
reactive oxyBen species
PATIENTS AND METHODS
Clinical characterizationI Patients were recruited from outpatient clinic or the Helsinki University
Central Hospital.The extent ofjointinflammation was recorded by using Kaarela's joint score index,
based on the presence of joint sweWing.Sixteen extra―articular tender points were studied using五
force BauBe doloriI¬eteri arter transformation of the read outs to z―units,an were added to a sinBle
tenderness score index.GeneralinflaΠlmatory disease activity was assessed usinB Hb,ESR,CRP and
Waaler―Rose test for RF.Various demoBraphic characteristics recorded included age,sex,weight and
heiBht.Dru8 treatlnent and disease duration were recorded as well.
Biochemical testsI BIood samples were taken arter overniBht Fast.Serum zinc and copper were
detefHlined by flame atonlic absorption spectrophotometry and selenium with a flameless AAS,Plasma
CSHpx waslneasured using 7 mM t―butyt hydroperoxide as substrate and H2°2 aS reaction initiator,
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wherearter NADPH tO NADP conversion was foIIOwed by absOrption spectrophotometry.Erythrocyte
SC)D activity was analyzed by fonowing superoxide prOduction in xanthine oxidase system in the
presence or NBT.Vitamin A(retinOl)was quantitated aFter HPLC spectrophotometrically by
measuring absOfbance at 205 nm whereas vitamin E(alpha―toCopherol)fluOrescemce intensity was
TReasured using excitation at 292 nm and erlission at 324 nmo Serum RBP and ceruloplasElin Were
measured by iHllnunodiffusiOn.
Dietarv assessmentt NutritiOnat therapist Or physician gave detailed oral Buidance to patients for a
throughOut one―week dietary recordinB in three periods during thfee weeks. Patients were also
provided with detailed written instruction with examplest The portion sizes were assessed using a
booklet including information or standards in Finiando Supplementation and home―cooking recipes
were recorded.Transrormation or nutrients was dOne suing Setti―N database covering aH rood items
available in Finiand.
Statistical analvsisi Univariate linear reBressiOn was used for comparision or two variable.If vahaЫes
were skewed arter iogarithmic and square rOOt transformations ror Poisson―distributed variables of
Arcus sin transfOrmation for variables presented as proportions,Spearman's rank co「relation was used
instead。
For comparision between groups,t―est was sed for nofmany distributed variables and Mann―
Whitney test ror skewed distributiOns. If there were mOre than two BroupS, One―way analysis or
variance and Kurskal―Wallis test,respectively,were used.
To study the independent efrects of various recorded variables on continuous variable`,such as the
concentration or a trace element or vitamin・rnultiple linear stepwise re8ression analysis in a rorward
manner was applied.TO adjust the material,if necessary,for e.g.aBe and sex,these were fOrces into
the model first.
In instead the independent errects or various fecOrded variables,including concentratiOns Of variOus
trace elements and vitamins,On cateBorial variable were assessed,rnultiple stepwise 10gistic reBressiOn
was applied, The cateBorial variable thus studied was the treatlnent with variOus types or d『ugs
(NSAID,chtOroquinei aurOtiOmalate,sulrasalazine,cOrticosteroidsi yes/no).
RESULTS AND DISCuSsloN
Serum zinc cOncentration was low in RA(10.22.O vs ll.91.8 umo1/1,p<0.001).Linear muitiple
reBression disclosed e.B.that joint scOre index(r=-0.403,399ノ。,pくo,01),1■b(「〓0.575,51為pくo,ool),
CRP(「=0,409,550/0,p<o.ol)and RF titer(r=-0.379,p<0,05)explained 599t of the variatiOn or serum
zinc in a age and sex adjusted model.Food intake did not affectserum zinc and serum serum zinc did
not predict medical treatrnent. These results su88est that disease activity dete「巨lineS serum zinc
whereas nutritiOn and medication are unilnportant as explanatory factors.
In anilnal modeis of arth『itis, zinc accumulates in liver due to induction of metanothionein.
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InterestinBIy, this metaHothionein is re8ulated by IL-1(=catabOlin, mononuclear ceH factor), a
cytokine reponsible for rnany tocal and systemic inflammatory events.Infusion of rёco binant IL-1
causes a decrease in seruri zinc.This biocherlical back8round and our observations su88est that,in
RA,Iow serum zinc is caused by IL-1.
Low serum zinc did not comprornise erythrocyte Cu,Zn―SOD,which was somewhat increased in
RA(4138 562 vs 3704 342 U/8 Hb,p<0.001),Interestingly,there was a corfelation between plasma
vitamin A and seruHl zinc(「=0.383,pく0 005i n=61)。We believe that this novel statistical associatiOn
has its pathophysioloBical explanation in that the synthesis or RBP in liver is regulated by zinc.
Accordingly,when we rneasured RBP in 30 of our patients,we found a correlation between vita■lin
A and RBP(R=0.942,p<0,001)aS expected,but also between RBP and serum zinc(r=0。440,pく0,02).
This suppofts the above rnentioned hypothesis and implies a lnarginal dericiency in functional zinc.
Serum copper was hiBh in RA (23,7 5,3 vs 17.64.9 umo1/1,pく0,001),exCept in patients over 65
years of age.The raw cofrelations of serum copper to disease activity parameters(ESR(f=0。323・
p=0101),CRP(p=0,363,pく0, 05),Hb(r=-0.272,pく0. 5)were Significant but the lnultiple reBression
picked up joint score index as the oniy signiricant・indep ndent predicting parameter(r=0.383,3396i
pく0.01)in age_ and sex―adjusted modcI.   InterestinBly, serum copper was high in patients on
DMARD(pく0.01),WhiCh drugs were not commonty used in patients over 65(pく0,01).
Serum copper had the highest correlation with cerulolasmin・which suBBes s this as the major
reason for hiBh seru「l copperin RA.InterestinBly,ceruloplasmin is part oF the above xnentioned IL―
1/1L-6-mediated acute phase response.The same stimulus may thus be responsible foriow serum zinc
and hiBh serum copper in RA. AssoCiation with ceruloplasElin aSsumes even more significance
because or the role or cerutoplasmin as one oF the rnajor antioxidants in the aqucous body humours.
Itis also noteworthy that the cytoplasπlic Cu,Zn―SOID is lnore sensitive to the availability or cOpper
than of zinc and accordingty. erythrocyte SOD activity was not decreased but in fact increased.
Cu,Zn―SC)D genc has been sequenced and at least in rat lung is induced in response to hyperoxia
(=OXidative stress),whiCh may suBgest that the increase in erythrocyte Cu,Zn―SOD is reactive
(erythrOid precursors in the bone rnarrow).
Serum copper wそュs also influenced by nutritional factors, namely zinc intake. This is st『ongly
suBBested by a cofrelation between plasma copper/copper intake ratio on zinc intake(r=-0.638,
p<0.001)but nOt On plasma zinc.
Serunl seteniuコn was low in RA and the extent or this decrease was associated with the extent of
joint inflammationo Selenium resides at the rour act"e sites of anti―oxidant enzyme CSHpx in
catalytica‖y active sclenocysteine residue at arhno acid 47.This is the only firmly established role
orselenium in man,However,plasma GSHpx was similarin RA and contrOis(308.64.2 vs 308.010.5
U/1) メゝBain, recent isolation and characterization or GSHpx gene made it possible to study gene
reButation using a promyelocytic human HL-60 celllineo Human《3SHpx gene appears to be regulated
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pOst_transcriptiona‖y, robably co_transtatiOna‖y・i  reponse to selentum availability.This together
with our findings lnay imply that selenium status in nOt cOmprottlized.
Serum vitamin A was low in RA(2.0430.671 vs 2.3360。597 umo1/1,p<0.05).There was a
signiricant correlatiOn between serum vitamin A and Kaarela's jOint scOre index in Spearman's rank
correlation test(「=o.330,p<0.Ol).However,when the above mentioned cofrelatiOn between serum
Zinc(―RBP)and vitamin A was taken intO muitiple linear reBressiOn,disease activity lossed its
explanatory valueo We extrapolate our findings sO that vitamin A is mainly reBulated by Zn_dependent
RBP synthesis in live「
.
Fat sotuble vitarnin E is intercalated in biO10gical lipid bitayer nlembranes so that the hydrophobic
tail anchors the molecule in such an orientation as to pOsition the reactive,Pnti-OXidant hydfOxyI
Broup at the pOlar hydrocarbon interphase Of the membrane. Here vita∬lin E excerts is fole as the
major lipid perO対dation chain―breaking anti―oxidant.vitamin E waslow in RA(17,78,2 vs 25。35.4
umO1/1・pく ),alsO iF vitamin E/(total cholesterol+triBIycerides)waS used as a variable.Howeve「
・
disease activity parameters were pOOr predictors,Due to its lipophilia,vitamin E stores are mainly in
fat tissue.These vitamin E stores are large compared to RDA.With these宙tamin E stores as a
llbuffer・1,seru■l vitarnin E and disease activity parameters are likely to get Out Of pace i.eo we interprit
our findings as increased cOnsumption or vitaπlin E by RA―associated lipid peroxidation in vivO.
When vitaπlin E reacts with fatty acid peroxyl radical, tocopheroxyl radical and ratty acid
hydroperoxide are Formed.TocOpheroxyl radical can be reduced back tO vitarnin E by water soluble
anti―Oxidants such as ascOrbate or BIutathione(recyctinB Of vitarlin E)and the seleno―enzyme GSHpx
catatyzes the reductiOn or unsaturated tipid hydroperoxide to lipid hydroxyacid.Thusi vitarnin】こand
CSHpx act in cOncert in ter耳ination Of lipid peroxidation. HOwever, vitarnin E is an essential
nutrient,whereas GSHpx may be reBulated at gene level as discussed above. This may be an
explanation Of the present rinding on iOw serum vitalnin E en face or normal plasma GSHpx.
Sulfasalazin acts as a superoxide scavenger. we fOund that GSHpx was hiBh in patients On
sulfasalazine compared tO Other RA patients(343.448.2 vs 299.632.9,pく0.002).AIso in multivariate
analysis sulrasalazine treatlnent was the best predictor Or GSHpx. These rindingS taken together
suBgest that in RA there may be an increased cOnsumption or GSHpx combined with inと
「eased
synthesis,a situtatiOn unmasked in suifasalazine treated patients,
ROS fOrmation in RA has been in particular assoctated with twO different BeneratOr systems:
NADPH Oxidase in the plasma membrane or neutrOphils and monocyte/maCrOphages(inflammation)
and xanthine Oxidase/hypoxanthine syste■l activa ed byュschceπ■a/reperfusion.ROS.ln particular
OTI, can have deletary efFects on unsaturated lipis, proteins and E)NA. although site speciric
production and prOduction in the bulk phase may atsO serve userul purpOses, such as enzyme
activation and microbicidal effects.oxidant stress seems tO cause consumption of anti-Oxidants like
vitamin E, vitarlin A, GSHpx etc even under physi0108iCal cOnditions ― ir stren uous physical
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exercises can be regarded as such.Our observations in RA are in line with the earlier observations
on the errect of oxidant stress in e.B. exercise and inflalnlnation. In some conditions the harmful
errects of oxidant stress can be recuperated or prevented by antioxidant treatment,so e.B.retrolental
fibroplasia in premature babies with respiratory distress synd「ome,who are expo ed to high oxygen.
Whether oxidanc damage in RA is prirnary or secondary or whether it can be modified by e.B,dietary
changes or supplementation feBIIns,is an open but interestinB question.
SUMMARY
The interactions at the interphase of nutrition,disease activity and medication in RA were studied.
In linear】nultiple regression,low serum zinc was predicted to 669もby six disease ac ivi y parameters
in age―and sex―adjusted modeto Low zinc is most likely due to IL-1-diven,metallothionein―
mediated sequestration in liver.AIso high seruni copper is explained by the same driving stilnulus in
that the highest correlation was on serum ceruloplas「lin,which being an acute phase reactant,is also
regulated by IL-1/1L-6.AccordinBIy,Cu,Zn―SC)]D,particularly sensitive to the availability or copper,
was not decreased.In contrast,high erythfocyte Cu,Zn―SOID suBgests a reactive synthesis in erythroid
precursors, perhaps by 02 driVen gene activation. Serum seleniuna was slightly lowered, whereas
plasma CSHpx activity was no「mah althOuBh human GSHpx gene is re8ulated by the availability of
selenium.
In patients on sulrasalazinei a superoxide scavenginB DMAR正),CSHpx was high,u maskinB an
underlying increase in GSHpx consumption in RA,This is in accordance with iow serum vitarlin E
(17.78.2 vs 25,35.4 umo1/1,pく0,05)intepreted to be a result of its consumption at the major lipid
peroxidation chain―breakinB anti―oxidant acting in concert with GSHpx.Vitaπlin A was also slightly
lowered(2.0430.671 ws 2.3360.597 umo1/1,pく0.05)but thiS Was best explained by the effect of low
zinc on RBP synthesis in liver.
Assessment of food intake usinB Setti―N nutritional da abase disclosed that seruln witaπ工n A was
also arrected by intake.The onty other nutritionany affected process was absorption or copper,、vhich
was decreased by high zinc intake, probably due to induction of metaHothionein in intestinal
epithetial ceWs. In addition to sulfasalazin effect on GSHpx,Iogistic model showed that DMARD
medication was associated with high serum copper. Otherwise medication and diet did not arrect
serum levels of the substances studied.
Itis not known at present,whethersome ofthe key antioxidants and trace elements are just markers
of underlying pathophysiological processes or whether they are consumed to the degree as to cause
harrn and motivate therapeutic intervention.Reactions and treatlnent potentials involved,however,
are highly complex.
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